FDA’s screening procedures will remain vigilant and will be augmented with screening of all Japanese shipments entering the United States. The agency has established special procedures to evaluate drugs originating from the ten prefectures in closest proximity to the Fukushima Daiichi nuclear plant.
FDA will physically examine for radiation all drugs originating from these ten prefectures. Based on the results of those physical examinations, FDA may also test products to determine if they are safe to admit into the U.S. FDA will also physically examine and test all injectable and inhalable drugs regardless of their place of origin within Japan.
